Concepedia

Ngozi Erondu

NE

Statistics

Publications

41

Citations

14K

H-Index

31

Active since

1983

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Janssen (United States)

Stanford University

Imperial College London

Ngozi Erondu is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicine, and pharmacotherapy.

Publications per year

1983–2023

41

Publications

41

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Mark Lebwohl, Bruce Strober, Alan Menter et al. · New England Journal of Medicine · 2015 · 806 citations · Full text

Medicine, Dermatology, Pharmacotherapy +10

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey et al. · The Lancet Diabetes & Endocrinology · 2018 · 643 citations · Full text

Medicine, Endocrinology, Nephrology +16

Biochemical and immunochemical evidence that the "major postsynaptic density protein" is a subunit of a calmodulin-dependent protein kinase.

Mary B. Kennedy, Mark K. Bennett, Ngozi Erondu · Proceedings of the National Academy of Sciences · 1983 · 615 citations · Full text

Life Sciences, Biochemistry, Neuroscience +7

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events

Kenneth W. Mahaffey, Bruce Neal, Vlado Perkovic et al. · Circulation · 2017 · 504 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

1–5 of 41